The Maharashtra Food and Drug Administration (FDA) has ignited a high-stakes debate over celebrity endorsements of Vimal ads, specifically targeting prominent Bollywood figures for their association with surrogate tobacco products. Under the leadership of commissioner Tukaram Mundhe, the regulatory body issued formal notices to superstar Shah Rukh Khan, veteran actor Ajay Devgn, and action star Tiger Shroff. The legal scrutiny centers on whether these actors are promoting harmful substances under the guise of selling flavored cardamom, a common practice within the industry that has long drawn criticism from health advocates.
Legal scrutiny over Vimal ads
While industry titans are now facing the heat, observers have frequently questioned why Akshay Kumar managed to avoid similar legal hurdles. The actor previously participated in campaigns for the brand but publicly stepped away in 2022 following intense backlash from his fanbase. Kumar issued a formal apology, stating that his conscience no longer allowed him to be associated with the product, effectively terminating his contract before government regulators could escalate the matter. His swift departure from the brand serves as a benchmark for how public pressure can influence celebrity decision-making.
The FDA’s move is part of a broader crackdown on misleading advertising, particularly where non-tobacco products are used to maintain brand recall for tobacco companies. By issuing these notices, the department is forcing a conversation about accountability. While celebrities often argue that they are simply endorsing a specific mouth freshener rather than a prohibited substance, the government’s stance suggests that the legal lines are blurring. Actors like Sunny Deol have also publicly distanced themselves from such endorsements, citing personal ethics and the potential harm to younger audiences who view these stars as role models.
As the legal process unfolds, the entertainment industry remains on edge regarding future endorsement deals. The FDA is examining whether these campaigns violate existing norms concerning public health and consumer protection. With the government clamping down, other high-profile actors are now re-evaluating their portfolios to avoid potential legal repercussions. For now, the spotlight remains firmly on the actors who have yet to disassociate from the brand, as regulators determine the next steps in their campaign to curb surrogate tobacco advertising.